Business
Sanofi's Pipeline Gains Momentum with Key Phase 3 Successes in Rare Disease and Immunology
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.